Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Plavix Pharmacogenomic Label Update May Help Lilly With Effient Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol/Sanofi blockbuster label was quietly updated two months ago to include precautionary statement and pharmacogenomic data about non-responders to Plavix. That label dovetails with Lilly's initial positioning of prasugrel.

You may also be interested in...

Lilly Will Play The Metabolism Card In Effient's Imminent U.S. Launch

Meanwhile, second-quarter sales of the oral platelet inhibitor outside the U.S. prove to be…thin.

Effient Labeling Could Give Edge Against Plavix Through Pharmacogenetics

Lilly/Daiichi Sankyo's prasugrel has carefully constructed label to control risk of bleeding - but it also includes a pharmacogenetic argument that Effient works in clopidogrel non-responders.

Lilly, Daiichi Explore Pharmacogenomic Marker For Prasugrel

Circulation study shows prasugrel metabolism unaffected by marker for Plavix non-response. Data won’t surprise FDA, but what will be the regulatory response?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts